Preoperative radiotherapy plus sur ... | Article | H1 Connect
[Clinical Trial: RCT]
Bonvalot S et al.
The Lancet Oncology. 2020 10; 21(10):1366-1377
https://doi.org/10.1016/S1470-2045(20)30446-0PMID: 32941794Classifications
- New Finding
Evaluations
While well-differentiated liposarcoma (WDLPS) rarely metastasizes, local recurrence of both retroperitoneal (RP) WDLPS and dedifferentiated liposarcoma (DDLPS) causes morbidity and impacts overall survival (OS), and thus efforts to improve local control are key. This prospective, multicenter phase III randomized controlled trial—the STRASS trial (EORTC 62092)—is the only completed trial to prospectively evaluate the impact of perioperative radiation therapy compared to surgery alone in RP soft tissue sarcoma. This trial randomized 266 patients with RP sarcoma (74.5% with liposarcoma, 97% of which were WDLPS/DDLPS) to preoperative radiotherapy followed by surgery or surgery alone and demonstrated a similar 3-year abdominal recurrence-free survival between the two arms (60.4% versus 58.7%, respectively) in the entire study population and in an exploratory post-hoc analysis of patients with liposarcoma.
This Recommendation is of an article referenced in a Faculty Review also written by Richard Riedel.
Relevant Specialties
Oncology
Sarcomas
Clinical Trials
- Trial registry title:
- Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Identifier:
- NCT01344018
- European Organisation for Research and Treatment of Cancer - EORTC Phase:
- N/A Gender:
- All Min Age:
- 18 Years Max Age:
- 120 Years Condition:
- Sarcoma Interventions:
- therapeutic conventional surgery, 3-dimensional conformal radiation therapy Countries:
- Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Norway, Poland, Spain, Sweden, United Kingdom, United States Official Title:
- A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS)
Sponsor:
Related Articles
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Mir O et al.2016 05
Latest recommendation by:
- New Finding
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
Tap WD et al.2016 Jul 30
Latest recommendation by:
- New Finding
- Novel Drug Target
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I et al.2014 Apr
Latest recommendation by:
- Confirmation
Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial.
Weiss AR et al.2020 08
Latest recommendation by:
- New Finding
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.
Bisogno G et al.2019 11
Latest recommendation by:
- New Finding
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
Schwartz GK et al.2013 Apr
Latest recommendation by:
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Piperno-Neumann S et al.2016 Aug
Latest recommendation by:
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
Schöffski P et al.2016 Apr 16
Latest recommendation by:
- New Finding
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP et al.2018 03
Latest recommendation by:
- New Finding
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.
Woll PJ et al.2012 Oct
Latest recommendation by:
- New Finding